ProKidney Advances Kidney Disease Treatment

ProKidney, a clinical-stage biotech company, has announced strategic updates to its Phase III development program for rilparencel, a promising investigational therapy aimed at preserving kidney function in patients with type 2 diabetes and advanced chronic kidney disease (CKD). The decision follows an in-depth review by internal and external experts, including consultations with former FDA officials and seasoned regulatory professionals.

Through this review, ProKidney concluded that under the Regenerative Medicine Advanced Therapy (RMAT) designation, rilparencel may qualify for FDA approval through an expedited pathway. The company now believes that successful completion of the ongoing Phase III REGEN-006 (PROACT 1) trial could be sufficient for the initial US approval of rilparencel. As a result, the previously planned Phase III REGEN-016 (PROACT 2) trial is no longer seen as necessary for initial registration.

This update signals ProKidney’s commitment to addressing the significant unmet need for effective treatments in patients with diabetes-related CKD, a condition with considerable clinical and economic impact. The potential expedited approval could bring relief to patients faster, positioning rilparencel as a critical therapy in a high-demand market.